HalcyGen sets sights on supergenerics

By Dylan Bushell-Embling
Friday, 20 June, 2008

Melbourne-based pharma HalcyGen (ASX: HGN) is in a good position to capitalise on the booming pharmaceuticals market, which is predicted to grow to nearly AUD$778 billion this year, the company said today.

In a presentation to a BioMelbourne Network CEO forum today, Halcygen CEO Dr Roger Aston said the company was well placed to take advantage of the changing trends in the pharmaceuticals market, due to HalcyGen's focus on supergenerics - proprietary modifications of generic copies of brand-name drugs.

These supergenerics contain the same active ingredient as the drugs they are modelled on, but improvements have been generally made to the dosage size, the formulation or the route through which they are administered.

For example, HalcyGen's key product, SUBA-Itraconazole Halcygen, requires half the dosage and causes significantly less severe side effects as the leading generic copy, Aston said.

Supergenerics are generally sold at a premium, due to the proprietary improvements. HalcyGen estimates that the typical product price-range of supergenerics is between $50-$500, compared to the typical price-range of $5-$50 for generics.

Supergenerics also obtain government approval up to five times faster than new drugs, as they are based on proven active ingredients, he said.

Related News

SEQ koala population carries immunity to retrovirus

Koalas from a population north of the Brisbane River appear to have evolved a unique genomic...

RSV immunisation program for babies slashes hospital stays

An Australian-first study has demonstrated the effectiveness of immunisation against respiratory...

A targeted treatment option for psoriasis

New research from MedUni Vienna paves the way for the development of a therapy that not only...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd